A blood test commonly used to detect foetal genetic abnormalities may help predict complications associated with pregnancy before symptoms develop, say researchers, including one of Indian-origin.
The study, published in the journal Epigenetics, links certain cell-free DNA signatures to adverse outcomes in pregnancy, including ischemic placental disease and gestational diabetes.
The findings are the first to show that genetic material shed from the placenta into the mother’s blood (circulating cell-free nucleic acids) during the first trimester of pregnancy could potentially be used to predict these potentially serious complications.
Although the analysis of genetic material in the mother’s blood has been used to screen for genetic abnormalities in a pregnancy, this is the first time these specific methods have been used as a way of a more accurate prediction.
“Our research points to a promising approach that could improve outcomes for mothers and their babies using existing technologies,” said study lead author Sherin Devaskar from the University of California, Los Angeles in the US.
“If confirmed in larger studies, cell-free DNA blood tests may help identify issues in the placenta as an indicator of a healthy mother and foetus,” Devaskar added.
For the study, the researchers followed a diverse group of pregnant women between February 2017 and January 2019, testing their blood periodically throughout gestation.
By the end of the study, 160 participants had given birth, with 102 maternal and 25 cord plasma samples were taken along the way.
They found that during the first-to-early second trimester, placenta-specific DNA increased among those women who went on to develop gestational diabetes.
They also identified several differentially expressed genes and were able to create a model with a predictive value for adverse pregnancy outcomes.
“The novelty of this research is being able to break down a mother’s DNA and be able to hone in on the health of the placenta – something that researchers have never been able to do before,” said Devaskar.
“This research warrants application of automated methodologies in multi-centre trials to improve future testing and screening for all women,” she noted.
IANS
